However, in people with mild cognitive impairment, the presence of depressive symptoms was tied to a lower likelihood of amyloid pathology (OR 0.73, 95% CI 0.61-0.89, P =0.001), Oomens and colleagues ...
The largest, most ethnically diverse, study of its kind has flagged hundreds of genetic variants that play a role in ...
The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major ...
Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.
A international joint research team of KAIST and the University of Michigan developed a digital biomarker for predicting ...
Already on its way to becoming a blockbuster drug, Johnson & Johnson’s Spravato has received another potential boost as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback